EQT Life Sciences led a $50m round in Avidicure.

EQT Life Sciences, a private equity firm, led a $50m round in Avidicure, a biotechnology company, with participation from Kurma Partners, BioGeneration Ventures, BOM, Curie Capital, and V-Bio Ventures. “Avidicure’s multifunctional antibodies provide a novel treatment modality with a unique, differentiated mode of action. These products are well-positioned to make a significant impact in the treatment of cancer patients.” Joern-Peter Halle, Avidicure Scientific Advisory Board.